<DOC>
	<DOCNO>NCT00136045</DOCNO>
	<brief_summary>The primary objective trial demonstrate rotigotine ( SPM 936 ) efficacious subject idiopathic restless leg syndrome ( RLS ) . Additional objective investigate safety tolerability rotigotine . The primary variable absolute change Baseline International Restless Legs Severity Scale ( IRLS ) sum score Clinical Global Impression-Global Improvement ( CGI ) Item 1 ( severity illness ) score end Maintenance Period . Subjects randomize receive either placebo , 2.25 , 4.5 6.75 mg/day rotigotine 1:1:1:1 ( active : placebo ) fashion . Approximately 450 subject enrol trial , participate approximately 50 site . The maximum duration trial approximately 8 month ( 3-week Titration Period , 6-month Maintenance Period , 7-day Taper Period , 30-day Safety Follow-Up Period ) . Subjects complete 6-month Maintenance Period eligible participate open-label extension trial . Subjects complete 6-month Maintenance Period choose participate open-label extension trial complete 3-day Safety Follow-Up Period . Two different patch size use ( 5 10 cm2 ) . Active patch contain either 2.25mg ( 5cm2 ) 4.5mg ( 10cm2 ) rotigotine .</brief_summary>
	<brief_title>Three Different Transdermal Doses Rotigotine Subjects With Idiopathic Restless Leg Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Idiopathic RLS History sleep disturbance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Idiopathic RLS</keyword>
</DOC>